Nonrespiratory complications of nusinersen-treated spinal muscular atrophy type 1 patients.

Nusinersen-treated SMA1 patients may sustain facial deformities, feeding problems, and severe scoliosis, all of which affect their respiratory system. Strict surveillance of these complications is essential to avoid further respiratory morbidity.